Two Sigma Advisers LP Sells 74,300 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Two Sigma Advisers LP lowered its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 7.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 913,500 shares of the biopharmaceutical company's stock after selling 74,300 shares during the period. Two Sigma Advisers LP owned about 0.99% of Ultragenyx Pharmaceutical worth $38,431,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Ultragenyx Pharmaceutical by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock worth $422,167,000 after purchasing an additional 89,389 shares in the last quarter. Invesco Ltd. raised its holdings in Ultragenyx Pharmaceutical by 1.5% in the 4th quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock worth $71,509,000 after purchasing an additional 25,487 shares in the last quarter. Alliancebernstein L.P. raised its holdings in Ultragenyx Pharmaceutical by 5.3% in the 4th quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock worth $68,487,000 after purchasing an additional 81,667 shares in the last quarter. Alyeska Investment Group L.P. raised its holdings in Ultragenyx Pharmaceutical by 23.1% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock worth $60,570,000 after purchasing an additional 269,733 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in Ultragenyx Pharmaceutical by 81.0% in the 4th quarter. Point72 Asset Management L.P. now owns 1,182,877 shares of the biopharmaceutical company's stock worth $49,764,000 after purchasing an additional 529,217 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Trading Up 0.3%

NASDAQ:RARE traded up $0.10 on Thursday, reaching $35.51. 514,307 shares of the stock traded hands, compared to its average volume of 825,531. The company has a market capitalization of $3.36 billion, a price-to-earnings ratio of -5.60 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a 12 month low of $29.59 and a 12 month high of $60.37. The company's fifty day simple moving average is $36.11 and its 200 day simple moving average is $41.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. During the same quarter in the prior year, the firm earned ($2.03) earnings per share. The business's revenue was up 28.0% compared to the same quarter last year. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on RARE shares. Cantor Fitzgerald restated an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Canaccord Genuity Group increased their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. Morgan Stanley increased their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. HC Wainwright reiterated a "buy" rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Finally, JPMorgan Chase & Co. increased their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $90.93.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 25,000 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $42.48, for a total value of $1,062,000.00. Following the transaction, the chief executive officer now owns 2,158,985 shares of the company's stock, valued at approximately $91,713,682.80. This trade represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Howard Horn sold 1,785 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the transaction, the chief financial officer now directly owns 106,169 shares in the company, valued at approximately $4,289,227.60. The trade was a 1.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold 125,405 shares of company stock worth $5,285,169 over the last three months. 5.50% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.